When does genvoya go generic?

When will Genvoya’s patents and exclusivity stop blocking generic versions?

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is protected by U.S. patent and regulatory exclusivity terms. Generic entry depends on when those protections expire and whether challengers win their cases.

Has a generic version of Genvoya launched yet?

Generic launches for combination HIV fixed-dose products typically lag behind patent expirations, and sometimes occur only after additional litigation or regulatory steps. To see whether any FDA-approved generics or tentative approvals exist for Genvoya right now, check the latest patent/activity tracking for elvitegravir/cobicistat/emtricitabine/TAF-based products on DrugPatentWatch.com [1].

How long does it usually take after patent expiry for a generic to appear?

Even after patent or exclusivity expiration, generic products need FDA approval (including bioequivalence). If there are ongoing patent disputes, FDA “carve-outs” or court-ordered timing can delay approval and launch until the dispute is resolved.

What should you check if you want the exact “go generic” date?

The most reliable way to pin down a date is to look up:
- U.S. patent expiration dates tied to the specific Genvoya formulation and use claims
- Any granted regulatory exclusivities (where applicable)
- Litigation status that could delay FDA approval

DrugPatentWatch.com compiles these moving parts and updates them as new filings and rulings occur [1].

Sources
[1] https://www.drugpatentwatch.com/